Odyssey is contributing its expertise in the biology of immune disorders. Evotec is contributing its data-driven drug discovery platform, compound libraries and technologies for high-throughput screening and computer-aided data analysis. Experimental data will be analysed using machine learning to identify and further develop suitable drug candidates more quickly. The specific aim of the collaboration is, for the time being, well ahead of any potential clinical development. Evotec is to provide validated hit series for several target structures, on the basis of which Odyssey can then drive forward its own drug discovery programmes. The companies did not disclose the financial details of the agreement. However, Evotec may receive milestone payments for each target structure if agreed research targets are met. The collaboration thus also illustrates how the business model in early-stage drug discovery is changing. AI-supported platforms are increasingly being combined with experimental methods and disease-specific expertise. For providers such as Evotec, this results in a model in which technological infrastructure and research output are directly linked to the success of individual development programmes.
News from "evotec" dated 6 August 2026